FDA Approves First Branded Bevacizumab for Wet Age-Related Macular Degeneration
After 20+ years of off-label use, bevacizumab-vikg (Lytenava) gets FDA approval for wet AMD, a leading cause of vision loss in older adults.
Summary
The FDA has approved bevacizumab-vikg (Lytenava) as the first branded ophthalmic formulation of bevacizumab specifically for neovascular (wet) age-related macular degeneration (AMD). Wet AMD is a progressive retinal disease and a leading cause of severe vision loss in older adults. For over two decades, eye doctors relied on off-label, compounded versions of bevacizumab — a VEGF inhibitor originally approved for colorectal cancer — because it worked and cost only $50–60 per injection. The newly approved branded version carries a list price of roughly $625 per dose in the U.K., raising cost concerns. Outlook Therapeutics plans to make the product available in the U.S. before the end of 2026. Common side effects include conjunctival hemorrhage, eye pain, and vitreous floaters.
Detailed Summary
Age-related macular degeneration is one of the most significant threats to vision in older adults, and the wet (neovascular) form progresses rapidly without treatment. For more than 20 years, ophthalmologists have managed this condition using compounded, off-label formulations of bevacizumab — a VEGF inhibitor developed for cancer — because it was effective and inexpensive. The FDA's approval of bevacizumab-vikg (Lytenava) marks a significant regulatory milestone, giving the retina community an officially sanctioned ophthalmic formulation for the first time.
Bevacizumab works by blocking vascular endothelial growth factor (VEGF), a protein that drives the abnormal blood vessel growth responsible for vision loss in wet AMD. The drug is administered as a monthly intravitreal injection at a dose of 1.25 mg. Its cancer counterpart, Avastin, received initial FDA approval in 2004, and off-label ophthalmic use followed within a year — a rare case of a cancer drug becoming a cornerstone of eye care.
The key concern with this approval is cost. Compounded bevacizumab has been remarkably affordable at $50–60 per injection, making it accessible across healthcare systems globally. Lytenava's U.K. list price of approximately $625 per dose signals a dramatic price increase that could strain patients and payers. FDA regulations around compounded drugs may now restrict access to the cheaper alternative, shifting patients toward the branded product.
The drug's approval history is notable: Outlook Therapeutics faced an FDA rejection in 2023 over manufacturing issues and insufficient clinical evidence, making this approval a hard-won regulatory success. Common adverse reactions include conjunctival hemorrhage (4%), eye pain (2%), and vitreous floaters (2%), which are consistent with intravitreal injection procedures generally.
For health-conscious older adults, wet AMD represents a serious age-related condition where early diagnosis and consistent anti-VEGF treatment are critical to preserving vision and quality of life. This approval expands the formal treatment toolkit, though cost accessibility remains an unresolved issue that patients and clinicians will need to navigate carefully.
Key Findings
- FDA approved bevacizumab-vikg (Lytenava) as the first branded ophthalmic bevacizumab for wet AMD.
- Branded version costs ~$625/dose vs. $50–60 for off-label compounded formulations, raising access concerns.
- Wet AMD is a leading cause of severe vision loss in older adults, making treatment access critical.
- Monthly 1.25 mg intravitreal injection; common side effects include conjunctival hemorrhage and eye pain.
- Approval follows a 2023 FDA rejection over manufacturing and clinical evidence concerns.
Methodology
This is a regulatory news report from MedPage Today, a credible medical journalism outlet. The article is based on an official company announcement from Outlook Therapeutics and references FDA approval and product labeling. No new clinical trial data is presented; evidence basis rests on the regulatory approval decision and prior clinical submissions.
Study Limitations
The article does not provide detailed clinical trial efficacy or safety data supporting the approval. U.S. pricing has not been confirmed, making cost-benefit assessments premature. Patients should consult their ophthalmologist and verify insurance coverage before assuming this option is accessible or superior to existing treatments.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: